Thursday, August 27, 2026

Technology Infrastructure Investment

2 articles

Neuromorphic Chip Deployments and $2B Packaging Investments Signal AI Hardware Maturation

Neuromorphic Chip Deployments and $2B Packaging Investments Signal AI Hardware Maturation

Intel's Hala Point system delivers 1.15 billion neurons in commercial neuromorphic deployments while Amkor invests $2 billion in Arizona advanced packaging capacity opening 2028. Enterprise AI platforms from VCI Global and BrainChip's Akida chips reach production scale as NVIDIA extends its roadmap through Rubin Ultra in 2027.

ViaNews Editorial Team (Finance)
AI Infrastructure Spending Surge: Semiconductor and Data Center Buildout Accelerates as Market Eyes $323B by 2030

AI Infrastructure Spending Surge: Semiconductor and Data Center Buildout Accelerates as Market Eyes $323B by 2030

The AI hardware infrastructure race is intensifying as semiconductor manufacturers, memory suppliers, and data center connectivity firms scale production to meet soaring demand from hyperscalers and enterprise workloads. With the AI processor market projected to expand from $43.7 billion to over $323 billion, companies like Credo Technology and Aehr Test Systems are posting bullish guidance while Google's custom silicon push challenges Nvidia's dominance.

ViaNews Editorial Team (Finance)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com